Skip to main content
Premium Trial:

Request an Annual Quote

Booster Boosts

People who received the Johnson & Johnson SARS-CoV-2 vaccine may have a stronger immune response when given a booster of either the Pfizer-BioNTech or Moderna vaccines, as compared to another J&J dose, NPR reports.

The National Institutes of Health-funded "mix and match" study, which has been posted to MedRxiv, enrolled 458 individuals who had previously been vaccinated with the Pfizer-BioNTech, Moderna, or J&J SARS-CoV-2 vaccines. Participants then received a booster dose of one of the three vaccines — not necessarily the same one they previously received. According to the researchers' analysis, all the boosters were immunogenic. They note, though, an mRNA-based booster led to a higher neutralizing response, particularly among individuals who had received an initial J&J vaccine.

The researchers caution, though, that their study was not designed to compare different responses and had a limited follow-up time.

As Business Insider notes, the study results come as a US Food and Drug Administration advisory panel is to meet to discuss boosters of the J&J and Moderna SARS-CoV-2 vaccines.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.